 On the eve of the 2017 Giro d'Italia, the UCI announced that both Stefano Pirazzi and Nicola Ruffoni had given adverse analytical findings (AAFs) for growth hormone-releasing peptides (GHRPs) in samples collected during out-of-competition doping tests conducted on 25 and 26 April 2017.With the team incurring first and second AAFs within a twelve-month period, the UCI aimed to enforce article 7.12.1 of the UCI Anti-Doping Rules, allowing for suspension of the team from 15 to 45 days - casting doubt on their Giro appearance.In October, 2017, the team announced that Michael Bresciani had tested positive for the banned diuretic furosemide in his first race as a professional.